🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for NMIBC

Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer NCT06889623NA1 site📍 Shanghai Changhai Hospital · Tests: Immediate postoperative chemotherapy A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing NCT07036731NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC NCT05410730Phase 1, Phase 21 site📍 Beijing Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-1501 A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer NCT07804056Phase 31 site📍 Prague Hamlet Pharma AB · Tests: Alpha1H, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Chemotherapy Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy NCT07000084Phase 360 sites📍 Birmingham📍 Fairbanks📍 Gilbert Alliance for Clinical Trials in Oncology · Tests: BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration NCT07307456Phase 21 site📍 Shanghai Changhai Hospital · Tests: Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT) LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve NCT04752722Phase 1, Phase 2102 sites📍 Birmingham📍 Scottsdale📍 Tucson enGene, Inc. · Tests: EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy NCT06351904Phase 13 sites📍 St Leonards📍 Melbourne📍 Melbourne Ractigen Therapeutics. · Tests: RAG-01 The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy NCT06388720Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Mitomycin-C, gemcitabine A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal NCT07784387n/a1 site📍 Lisbon Janssen-Cilag Farmaceutica Ltda. Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial Bladder Tumors NCT07860398NA1 site📍 Herlev Optheras AS · Tests: ATLAS system A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer NCT06735287NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: bladder sparing set, RC A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) NCT06108492Phase 11 site📍 Shanghai Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-2005 DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr NCT04106115Phase 1, Phase 27 sites📍 Cambridge📍 London📍 London University College, London · Tests: Durvalumab, S-488210/S-488211 Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC NCT05123625NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Reduce surgical procedures A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer NCT07122414Phase 1, Phase 212 sites📍 Beijing📍 Beijing📍 Fuzhou Suzhou Forlong Biotechnology Co., Ltd · Tests: FL115, FL115+BCG Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients NCT06696794Phase 33 sites📍 Wuhan📍 Wuhan📍 Xiangyang Shaogang Wang · Tests: Mitomycin C (MMC), Normal Saline (Placebo) A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC NCT07726992Phase 32 sites📍 Beijing📍 Guangzhou Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-1501+BCG, Placebo +BCG Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? NCT07625527Phase 24 sites📍 Tianjin📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC NCT07322263Phase 21 site📍 Iowa City Michael A. O'Donnell · Tests: Intravesical Gemcitabine and Docetaxel The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection NCT06287541NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer NCT05951179Phase 278 sites📍 Homewood📍 Phoenix📍 Queen Creek Protara Therapeutics · Tests: TARA-002 Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy NCT06972615Phase 21 site📍 CABA BLATAM · Tests: intravesical Chemotherapy docetaxel/gemcitabine The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer NCT07130578n/a2 sites📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: urine tumor DNA/RNA testing Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC NCT06567743Phase 280 sites📍 Gilbert📍 Phoenix📍 Tucson CG Oncology, Inc. · Tests: Cretostimogene Grenadenorepvec Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study NCT07339761NA1 site📍 Aarhus University of Aarhus · Tests: Sexological Support RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects NCT05943379Phase 21 site📍 Beijing RemeGen Co., Ltd. · Tests: RC48-ADC in Combination with gemcitabine A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer NCT06319820Phase 3193 sites📍 Little Rock📍 Los Alamitos📍 Los Angeles Janssen Research & Development, LLC · Tests: TAR-210, Gemcitabine, MMC A Phase I Intravesical PPM Therapy for NMIBC NCT05519241Phase 11 site📍 Boston VA Office of Research and Development · Tests: PLZ4-coated paclitaxel-loaded micelles (PPM) 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors NCT07898033Phase 31 site📍 Petah Tikva dmitry enikeev · Tests: En Bloc Resection of Bladder Tumor, Trans Urethral Resection of Bladder Tumor
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy